Down-regulation of PRDX4 protein expression was correlated with increaed malignancy of clear cell renal cell carcinoma
10.3781/j.issn.1000-7431.2017.33.497
- Author:
Zhuangfei CHEN
1
Author Information
1. Department of Urology, Nanfang Hospital, Southern Medical University
- Publication Type:Journal Article
- Keywords:
Peroxiredoxin 4;
Prognosis;
Proteomics;
Renal neoplasms
- From:
Tumor
2017;37(12):1304-1312
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To screen the differentially expressed proteins in clear cell renal cell carcinoma (ccRCC), and to investigate its clinical significance. Methods: The differentially expressed proteins in 15 cases of ccRCC and their adjacent renal tissues were screened by two-dimensional fluorescence difference in gel electrophoresis combined with mass spectrometry (2-D DIGE-MS). The expression levels of differentially expressed proteins screened by 2-D DIGE-MS in 45 cases of ccRCC and their adjacent tissues were examined by Western blotting. The expression levels of this differentially expressed proteins in 152 specimens of ccRCC and 40 specimens of adjacent tissues were detected by immunohistochemistry. The correlations of this protein expression with the clinicopathologic features and prognosis of ccRCC patients were analyzed. Results: Proteomics screening results showed that the expression level of peroxiredoxin 4 (PRDX4) was significantly different in ccRCC and its adjacent tissues; compared with the adjacent tissues, PRDX4 expression was significantly down-regulated in ccRCC tissues (P < 0.05); and the expression level of PRDX4 in the adjacent tissues was 3.979 times higher than that in ccRCC tisseus. Western blotting showed that the expression level of PRDX4 in ccRCC tissues was significantly lower than that in adjacent tissues (t = 12.810, P < 0.001). Immunohistochemistry showed that the positive expression rate of PRDX4 in ccRCC tissues was significantly lower than that in the adjacent tissues [36.8% (56/152) vs 87.5% (35/40), ?2 = 32.594, P < 0.001]. Furthermore, the expression level of PRDX4 was correlated with tumor grade (?2 = 6.802, P = 0.033) and distant metastasis (?2 = 3.925, P = 0.048), but was not related to gender, age, T stage, lymph node metastasis and recurrence (all P > 0.05). The patients with lower expression of PRDX4 had high grade of ccRCC (? = -0.211, P = 0.009) and distant metastasis (? = -0.161, P = 0.048). The 5-year survival rates of patients with positive and negative expression of PRDX4 were 75.3% and 62.7% (P = 0.862), respectively. Conclusion: PRDX4, as a differentially expressed protein in ccRCC, may be involved in the formation and development of renal cancer, and its down-regulation is correlated with the increased malignancy of ccRCC.